Differences of SARS-CoV-2 serological test performance between hospitalized and outpatient COVID-19 cases.

ABSTRACT:

Background

Serological severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody assays differ in the target antigen specificity, e.g. of antibodies directed against the viral spike or the nucleocapsid protein, and in the spectrum of detected immunoglobulins. The aim of the study was to evaluate the performance of two different routinely used immunoassays in hospitalized and outpatient COVID-19 cases.

Methods

The test characteristics of commercially available spike1 protein-based serological assays (Euroimmun, EI-assays), determining IgA or IgG and nucleocapsid-based assays (Virotech, VT-assays) determining IgA, IgM or IgG were compared in 139 controls and 116 hospitalized and outpatient COVID-19 cases.

Results

Hospitalized COVID-19 patients (n = 51; 115 s

SUBMITTER: Wolf J 

PROVIDER: S-EPMC7642750 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature